Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2646)	5/3/2011 12:44:08 PM
From: software salesperson	2 Recommendations Read Replies (1) \| Respond to of 3202

5/3/11 cc notes 1. Opening remarks ( by Rich Levy) Rux NDA and MAA in June; NDA expected to receive 6 month review; currently preparing for expected advisory meeting; launch later this year Best of ASCO presentation with cc follow-up in evening Both Comfort abstracts to be presented in Europe Rux MF - - initiated low platelet count trial Rux advanced PV - - most US sites active; NVS enrolling Other Rux P1 , P2 - - other leukemias, other hematological malignancies, solid tumors with COG and MD Anderson Rux pancreatic and lymphoma - - both 2nd ½ 2011 RA - - LLY to complete enrollment by 2nd ½ 2011 Sheddase - - analysis of tissue samples mid-year to determine whether to proceed with P3 IDO - - P1 solid tumors; dose escalation complete by year-end; also, melanoma and ovarian likely for P2 CMET - - trying to find maximum tolerated dose Another oncology IND coming Cash 3/31/11 = 383 M 2. q & a - - all rux, unless noted (i ) plans for commercial buildout? NVS role? 1st to market advantage? - - hiring regional managers and salespeople by 3rd q; working on global brand name; allows us to shape and define market for 2-3 years (ii) what are physicians most focused on? - - spoke to > 1000; thrombocytopenia, shrink spleen by 10%, relief of symptoms, efficacy, manage side effects; anemia not a focus (iii) comfort 1 patients remain on drug? - - vast majority; minimal dropout rate (iv) technology used for sustained release(SR) version? Once a day? - - smoother profile; lower peak; need more than 1 trial to get to market; protect market base against future once a day competitor; greater compliance (v ) ASCO and EHA presentations different? - - no (vi) RA - - thoughts on PFE’s deaths? JAK1/2 vs pan JAK profiles? - - unsure; our JAK trials have older patients with CV diseases and we haven’t seen CV problems; RA patients at more risk for CV disease in general; encouraged by PFE’s efficacy and safety profile; we haven’t seen heart disease or respiratory failures; doesn’t know whether JAK1/2 vs pan JAK makes a difference (vii) PV - - enrollment in Response study? - - working with US academic centers; NVS sites enrolling; running slightly behind year-end start goal (viii) CMET milestone for what? - - no direct answer (ix) rux pricing ? - - no direct answer (x) NVS have expanded access in Europe? - - not sure; after they file, some countries will have (xi) SR formulation show benefit for myelosuppression? - - no (xii) NVS use US data to file? - - yes (xiii) dosing for low platelet study? - - 5 mg BID not as effective as high dose; 10 mg BID almost as effective (xiv) what will be the most successful dose for low platelet count patients? - - expect 10 mg BID (xv) those patients who get thrombocytopenia, are they more sensitive to the drug or is it their starting point? - - starting point (xvi) other data in addition to ASCO or EHA? - - no 3. impressions solid call; highlights were: best at ASCO; no heart disease or respiratory failures seen sales